CD79A and cranioectodermal dysplasia: In the absence of pretreatment tTG-IgA titers, pretreatment histological confirmation, and HLA genotyping, we cannot definitively discern whether the patients in this study had de novo CeD (asymptomatic or subclinical) that progressed to symptomatic CeD in the setting of ICIs.3 Additionally, T-cell receptor sequencing to assess for clonal expansion will be crucial in expanding our understanding of ICI-CeD compared with usual CeD and ICI-Duo.